pertuzumab
1 clinical trial
1 product
14 abstracts
1 indication
Indication
Breast CancerAbstract
DESTINY-Breast07: Dose-expansion interim analysis of T-DXd monotherapy and T-DXd + pertuzumab in patients with previously untreated HER2+ mBC.Org: Gustave Roussy Cancer Center, Université Paris-Saclay, Villejuif, France, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN,
Clinical trial
DETECT V / CHEVENDO A Multicenter, Randomized Phase III Study to Compare Chemo- Versus Endocrine Therapy in Combination With Dual HER2-targeted Therapy of Herceptin® (Trastuzumab) and Perjeta® (Pertuzumab) Plus Kisqali® (Ribociclib) in Patients With HER2 Positive and Hormone-receptor Positive Metastatic Breast Cancer.Status: Active (not recruiting), Estimated PCD: 2025-01-31
Abstract
Unveiling the relationship between the UGT2B gene family and neoadjuvant treatment response in patients with HER2-positive breast cancer.Org: Instituto Biomedicina Sevilla, Institute of Biomedicine of Seville (IBiS), Andalusian - Roche Network Mixed Alliance in Precision Medical Oncology,
Abstract
Phase II/III study of paclitaxel/carboplatin alone or combined with either trastuzumab and hyaluronidase-oysk or pertuzumab, trastuzumab, and hyaluronidase-zzxf in HER2 positive, stage I-IV endometrial serous carcinoma or carcinosarcoma (NRG-GY026).Org: The GOG Foundation, Inc., Women and Infants Hospital, Brown University, Spectrum Health Cancer Center, LSU Health School of Medicine, Department of Obstetrics, Gynecology, and Reproductive Sciences Yale University School of Medicine,
Abstract
A prospective, open-label, single-arm phase II clinical study of inetetamab in combination with pyrotinib and albumin-bound paclitaxel for the neoadjuvant treatment of patients with HER2+ early and locally advanced breast cancer.Org: Department of Thyroid, Breast, and Vascular Surgery at Xijing Hospital, Air Force Medical University,
Abstract
Optimal neoadjuvant treatment and prognostic factors in patients with HR-positive/HER2-positive early or locally advanced breast cancer: A national real-world study in China.Org: Department of Breast Disease, Henan Breast Cancer Center, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China, Henan Breast Cancer Center, Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China,
Abstract
The subgroup analysis by age and geriatric assessment in a phase III study comparison of trastuzumab emtansine with trastuzumab, pertuzumab, and docetaxel in older patients with advanced stage HER2-positive breast cancer (JCOG1607 HERB TEA study).Org: National Center for Global Health and Medicine, Shimane University Hospital, Japan Clinical Oncology Group Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan, National Cancer Center Hospital East, Kashiwa, Japan, Clinical Research Support Office, National Cancer Center Hospital, Tokyo, Japan,
Abstract
Safety and preliminary efficacy of GQ1001, a next generation HER2-targeting ADC, combined with pyrotinib in pretreated patients with HER2-positive metastatic breast cancer: A phase 1b clinical trial.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Fudan University Shanghai Cancer Center, Shanghai, China, Gracell Biotechnologies, Ltd.,
Abstract
Deciphering tumor microenvironment dynamics in HER2-amplified refractory metastatic colorectal cancer in the TRIUMPH trial.Org: Hiroshima University Hospital, Department of Surgery, NHO, Osaka National Hospital, Department of Gastrointestinal and Medical Oncology, National Hospital Organization Kyushu Cancer Center, Department of Cancer Chemotherapy, Hokkaido University Hospital Cancer Center, Department of Gastrointestinal Medical Oncology, NHO Shikoku Cancer Center,
Abstract
Unraveling the synergistic mechanisms of pyrotinib in combination with trastuzumab: Insights from the PHILA trial.Org: National Cancer Center Hospital East, Kashiwa, Japan, National Clinical Research Center for Cancer, Cancer Hospital of Chinese Academy of Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, State Key Laboratory of Molecular Oncology,
Abstract
Is early inclusion of neratinib with HER blockers possible in the treatment of stage 4 HER2 positive cancer?Org: Ilboza medical, Uzbekistan,
Abstract
Gene expression signatures, stromal tumor infiltrating lymphocytes (sTILs), and change in tumor cellularity to predict pathological complete response (pCR) after 12 week de-escalated neoadjuvant endocrine therapy (ET) vs paclitaxel + dual HER2 blockade in the WSG-TP-II trial.Org: West German Study Group, Moenchengladbach, Germany, Klinikum Dortmund gGmbH, Medical School Hannover,
Abstract
Invasive disease free survival and brain metastasis rates in patients treated with neoadjuvant chemotherapy with trastuzumab and pertuzumab.Org: Memorial Sloan Kettering Cancer Center,
Abstract
HER2CLIMB-05: Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer.Org: Sarah Cannon Research Institute at Tennessee Oncology, PLLC, Hospital General Universitario Gregorio Marañón, Mayo Clinic, European Institute of Oncology, Yonsei Cancer Center, Yonsei University Health System,
Product
Perjeta